Enterprise value to EBITDA forward of MaxCyte, Inc. – NASDAQ:MXCT
This article provides the enterprise value to EBITDA forward for MaxCyte, Inc. (NASDAQ: MXCT). It appears to be a financial data snippet from TradingView, indicating the value and any changes for the specified financial metric. The content itself seems to be a display of this single financial data point without further analysis.
MaxCyte stock leans on platform demand. Nasdaq listing stays central.
MaxCyte Inc. (MXCT) is a Nasdaq-listed cell-engineering company whose investment case focuses on the adoption and usage of its Flow Electroporation platform by biopharma and research customers. Without new immediate catalysts, the company's performance is tied to execution, customer adoption, and the recurring use of its technology in drug discovery and cell therapy development. The stock's Nasdaq listing provides transparency through SEC disclosures, making it easier for investors to track its operational progress.
Price to book forward of MaxCyte, Inc. – NASDAQ:MXCT
This article provides a brief snapshot of the "Price to book forward" metric for MaxCyte, Inc. (NASDAQ:MXCT) on TradingView. It shows the period, value, and change percentages for this financial indicator. The content is concise and focused solely on this specific financial data point.
Price to sales forward of MaxCyte, Inc. – LS:A2AGVE
This article provides access to the "Price to sales forward" financial metric for MaxCyte, Inc. (A2AGVE) on the TradingView platform. It highlights that market data is provided by ICE Data Services and FactSet, and SEC filings by Quartr. The content mainly consists of navigation links and various platform features, with minimal direct data presented.
MXCT Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for MaxCyte, Inc. (MXCT) stock, based on analyst ratings and current market data. It includes information on the company's past performance, stock volatility, market capitalization, earnings, revenue, and future outlook, as well as frequently asked questions about investing in MXCT.
MYE0 Forecast — Price Target — Prediction for 2027
This article provides a forecast for MaxCyte, Inc. (MYE0) stock, including analyst price targets, past financial performance, and key company metrics. It details the stock's highest and lowest recorded prices, upcoming earnings reports, and financial statistics such as revenue, net income, and EBITDA. The article also confirms that MaxCyte, Inc. does not pay dividends and offers information on how to trade its shares.
MYE0 Forecast — Price Target — Prediction for 2027
This article provides a forecast for MaxCyte, Inc. (MYE0) stock, including analyst price targets and ratings. It details historical stock performance, upcoming earnings dates, and financial metrics like EPS, revenue, net income, and EBITDA. The content also answers frequently asked questions about buying shares and dividend information.
MaxCyte, Inc. Actuals & Estimates (NASDAQ:MXCT)
This article provides an overview of MaxCyte, Inc. (NASDAQ:MXCT) stock, including its current price, performance, and analyst forecasts. It covers financial data, market capitalization, earnings reports, and technical analysis, noting that MXCT's stock has shown recent gains but a significant decrease over the last year. The company's next earnings report is expected on August 12, 2026.
VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering
VectorBuilder and MaxCyte have formed a strategic partnership to create a new gene delivery solution for ex vivo cell engineering. This collaboration integrates VectorBuilder’s MiniVec™ plasmid system with MaxCyte’s Flow Electroporation® technology, aiming to enhance cell viability and gene expression while improving manufacturability, scalability, and safety for cell therapies like CAR-T. Preliminary data shows significantly increased cell viability and gene expression, positioning the platform as a robust solution for clinical-grade applications.
MaxCyte (MXCT) grants RSUs and stock options to director
MaxCyte (MXCT) director John Joseph Johnston was granted 30,421 restricted stock units and stock options for 49,579 shares as part of his annual non-employee director compensation. The RSUs will vest on June 17, 2027, contingent on his continued service, and the stock options have an exercise price of $1.13 per share and expire in 2036. Following these transactions, Johnston's direct holdings in MaxCyte common stock amount to 201,581 shares.
MAXCYTE (MXCT) director Cynthia Collins receives RSUs and 49,579-share option grant
MAXCYTE director Cynthia Collins was granted 30,421 restricted stock units and a stock option for 49,579 shares at an exercise price of $1.13 per share, expiring in 2036. These equity awards, made on June 17, 2026, are part of the company's Equity Grant Policy for non-employee directors. The RSUs will vest on June 17, 2027, contingent on her continuous service, and she now directly holds 111,310 shares of common stock.
Form 4 MaxCyte Inc For: 22 June By Investing.com
This article from Investing.com is a regulatory filing update, specifically a Form 4 for MaxCyte Inc, dated June 22. It primarily serves as a notice of the filing without providing further details on the content of the form itself. The content primarily consists of market data and unrelated news, often found in a financial news feed.
MaxCyte (MXCT) director receives RSUs and options in annual equity grant
MaxCyte Inc. director Stanley C. Erck received an annual equity grant comprising 30,421 restricted stock units (RSUs) and an option to purchase 49,579 shares at $1.13 per share. The RSUs will vest on June 17, 2027, contingent on his continued service. Following this grant, Erck's direct common stock holdings total 428,749 shares.
MAXCYTE (NASDAQ: MXCT) director receives RSU and option grants as annual equity award
MAXCYTE (NASDAQ: MXCT) director Douglas Richard was granted 30,421 Restricted Stock Units (RSUs) and 49,579 stock options with an exercise price of $1.13 per share. These grants are part of the company's annual equity award policy for non-employee directors, with the RSUs vesting on June 17, 2027. This transaction represents compensation and not an open-market trade, aligning the director's incentives with long-term company performance.
MaxCyte (MXCT) director receives RSUs and 49,579 stock options in new grant
MaxCyte (MXCT) director Brooke William W was granted 30,421 restricted stock units (RSUs) and stock options for 49,579 shares of Common Stock at an exercise price of $1.13 per share. The RSUs vest on June 17, 2027, contingent on his continuous service, and the stock options expire on June 16, 2036. Following these equity awards, Brooke William W directly holds 181,300 shares of MaxCyte Common Stock.
MaxCyte (MXCT) director receives RSU and stock option grant
MaxCyte (MXCT) director Yasir B. Al-Wakeel was granted 30,421 restricted stock units (RSUs) and stock options for 49,579 shares at an exercise price of $1.13 per share. These equity awards are part of his annual non-employee director compensation package, with the shares vesting on June 17, 2027, contingent on his continued service. Following the RSU grant, Al-Wakeel directly owns 80,998 shares of Common Stock.
MaxCyte (MXCT) director awarded RSUs and stock options in annual grant
MaxCyte, Inc. director Rekha Hemrajani received an annual equity grant comprising 30,421 restricted stock units (RSUs) and 49,579 stock options with a strike price of $1.13, expiring in 2036. These awards, part of the non-employee director policy, vest on June 17, 2027, contingent on her continued service. Following these transactions, her direct common stock holdings total 70,314 shares.
Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT)
Craig-Hallum analyst Matt Hewitt has reaffirmed a Buy rating on MaxCyte (MXCT). Despite recent negative insider sentiment, the company reported Q1 revenue of $9.65 million and a GAAP net loss of $4.75 million, with an analyst consensus of Moderate Buy and a price target of $4.00.
MaxCyte Stock - chart levels and volatility on a quiet news day
MaxCyte stock traded on Nasdaq without new corporate headlines, leading analysts to focus on its chart performance, volatility, and key moving averages. The company, which develops cell-engineering technologies for biopharma partners, is in a period of consolidation. Investors are watching for fundamental catalysts, as the stock moves within a corridor defined by its spring lows and early-summer highs.
MaxCyte shareholders elect directors and approve auditor at annual meeting
MaxCyte, Inc. announced the results of its 2026 annual meeting, where shareholders elected three Class II directors—Patrick Balthrop, Cynthia Collins, and Stanley Erck—and ratified CohnReznick LLP as its independent auditor for the fiscal year ending December 31, 2026. Despite the stock being down 27% year-to-date, the company maintains a strong balance sheet with more cash than debt, though it continues to burn cash. These decisions follow recent positive financial results and regaining compliance with Nasdaq's minimum bid price requirement.
MaxCyte shareholders elect directors and approve auditor at annual meeting By Investing.com
MaxCyte, Inc. held its 2026 annual meeting where shareholders elected three Class II directors—Patrick Balthrop, Cynthia Collins, and Stanley Erck—and ratified CohnReznick LLP as their independent auditor for the fiscal year ending December 31, 2026. Despite the stock being down 27% year-to-date, the company maintains a strong balance sheet with more cash than debt, though it continues to burn cash. These governance updates follow recent positive financial results and regaining compliance with Nasdaq's minimum bid price requirement.
MaxCyte, Inc. (MXCT) Announces Results of Shareholder Vote and Audit Firm Ratification – June 17, 2026
MaxCyte, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where shareholders re-elected two Class II Directors and ratified CohnReznick LLP as the independent auditor for the fiscal year ending December 31, 2026. These decisions signal continuity in leadership and financial oversight. The company continues to operate as an "Emerging Growth Company," benefiting from reduced regulatory burdens, and the outcomes are not expected to cause immediate significant share price changes but support long-term investor confidence.
MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for MaxCyte Inc (MXCT) as of FY2024 and projected FY2025 data. It categorizes revenue by business segments, showing product sales (56.59%), licenses (37.45%), and other (5.95%) for a total of $33.03 million. The report also highlights the regional distribution of revenue, with 63.82% from within the United States and 36.18% from outside the United States.
MaxCyte Regains Nasdaq Compliance After Bid Price Recovery
MaxCyte (MXCT) has regained compliance with Nasdaq's minimum bid price requirement after its shares traded above $1.00 for ten consecutive business days. The company had initially received a non-compliance notice on March 16, 2026, due to its stock price falling below $1.00 for 30 consecutive trading days. While the immediate risk to its Nasdaq listing has been removed, an AI analyst from TipRanks assesses MXCT as Neutral, citing persistent losses and cash burn despite strong gross margins.
MaxCyte Inc (MXCT) Institutional Confidence
MaxCyte Inc (MXCT) has an institutional shareholding score of 7.00, placing it 79th out of 203 in the Healthcare Equipment & Supplies industry. Institutional investors hold 74.61% of the shares, a slight decrease of 0.07% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.86% of outstanding shares.
MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates
MaxCyte Inc (MXCT) has an earnings forecast score of 8.29, ranking 53rd in the Healthcare Equipment & Supplies industry. Analysts have an average price target of $5.72, with forecasts ranging from $5.00 to $9.00, suggesting a significant upside of 260.31%. Most analysts rate MXCT as a "Buy" based on 7 ratings.
MaxCyte (NASDAQ: MXCT) investors reelect board and ratify auditor
MaxCyte, Inc. (NASDAQ: MXCT) shareholders reelected three Class II directors—Patrick Balthrop, Cynthia Collins, and Stanley Erck—and ratified CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes took place at the company's 2026 annual stockholder meeting on June 17, 2026, with the auditor ratification receiving over 70 million votes in favor. This outcome, detailed in an 8-K filing, indicates strong investor support for the company's board composition and auditor selection.
MaxCyte regains compliance with Nasdaq minimum bid price rule
MaxCyte, Inc. (NASDAQ:MXCT) has regained compliance with the Nasdaq Stock Market's minimum bid price requirement. The company received notice on June 10 that its common stock's closing bid price was $1.00 or greater for 10 consecutive business days, satisfying Nasdaq Listing Rule 5450(a)(1). This development follows a prior notification of non-compliance in March due to the stock trading below $1.00 for 30 consecutive days, yet has outperformed analyst expectations in Q1 2026.
MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard
MaxCyte regained compliance with Nasdaq's Listing Rule 5450(a)(1) after its closing bid price remained at or above $1.00 for ten consecutive business days from May 27 to June 9, 2026. This action resolves the prior deficiency concerning the minimum bid price requirement. The matter is now closed,
MaxCyte (NASDAQ: MXCT) restores Nasdaq minimum bid-price compliance after warning
MaxCyte (NASDAQ: MXCT) has regained compliance with Nasdaq's minimum bid-price requirement after its stock closed at or above $1.00 for 10 consecutive business days, from May 27 to June 9, 2026. The company had previously received a warning in March 2026 for its common stock closing below $1.00 for 30 consecutive trading days. This resolution removes the immediate delisting risk and closes the specific compliance matter.
MXCT - MaxCyte Inc Stock Price and Quote
This page provides a comprehensive overview of MaxCyte Inc. (MXCT) stock, including its current price, financial metrics, analyst ratings, and recent news. It details key financial figures such as market cap, income, and sales, alongside performance indicators and insider transaction data. The article also lists historical analyst actions and recent press releases related to the company's earnings, strategic agreements, and corporate changes.
MaxCyte outlines $30M-$32M 2026 revenue outlook as board authorizes $10M share repurchase program
MaxCyte has projected a revenue outlook of $30 million to $32 million for 2026. This announcement comes as the company's board of directors authorized a new $10 million share repurchase program, aiming to return value to shareholders.
MaxCyte Inc stock (US57777K1060): cell-therapy enabler after recent earnings update
MaxCyte Inc provides cell-engineering platforms crucial for biotech and pharmaceutical companies developing cell therapies. The Nasdaq-listed company generates revenue from instrument sales, consumable cartridges, and long-term licensing deals, which include milestone payments and royalties. MaxCyte’s technology offers a scalable alternative to viral vectors, making it an important player in the growing cell and gene therapy market.
MaxCyte Inc stock (US57777K1060): recent volatility and growth hopes in cell therapy tools
MaxCyte Inc (MXCT) stock has shown recent volatility with increased trading volumes, as the company expands partnerships for its cell-engineering platforms. MaxCyte provides electroporation platforms for cell therapy, gene editing, and biopharma research, generating revenue through instrument sales, consumables, and licensing agreements with potential milestone payments and royalties. The company operates as a "picks-and-shovels" supplier for the growing cell and gene therapy industry, benefiting from the broad adoption of its technology rather than bearing the risks of individual drug development.
MAXCYTE, INC. 1Q 2026: Revenue $9.65M, EPS ($0.04) — 10-Q Summary
MAXCYTE, INC. reported Q1 2026 results with revenue of $9.65M and a diluted EPS of ($0.04), showing a 7.1% decrease in revenue year-over-year but a 53.7% improvement in net income due to reduced losses. The revenue decline was primarily due to a 25% drop in core revenue, somewhat offset by a 60% rise in SPL milestone and royalty revenue. The company launched ExPERT DTx in February 2026 and implemented operational efficiency measures to reduce expenses and extend its financial runway.
MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives
MaxCyte (MXCT) reported Q1 2026 revenue of US$9.7 million and a basic EPS loss of US$0.04, with the net loss narrowing compared to Q1 2025. Despite revenue forecasts and a long runway of SPL programs, analysts do not predict profitability within the next three years. The company currently trades at a 3.6x P/S, exceeding its peer average, while still incurring heavy losses, leading to skepticism about its valuation.
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday
This article highlights five stocks to watch on Wednesday, May 15, 2026, based on their upcoming earnings reports or recent financial results. Cisco Systems (CSCO), MaxCyte (MXCT), Alibaba Group (BABA), Nextpower Inc. (NXT), and Vishay Intertechnology (VSH) are featured, with details on expected earnings, revenue, and their after-hours stock performance.
MaxCyte Reports Q1 2026 Results, Launches Share Buyback
MaxCyte reported a 7% year-on-year revenue decrease in Q1 2026 to $9.7 million, with core business revenue down 25% but SPL program revenue increasing. The company's net loss decreased to $4.8 million, and it maintains full-year revenue guidance while announcing a $10 million share repurchase program. Analysts currently rate MXCT as a 'Buy' with a $4.00 price target.
River Global Investors builds 6.1% MaxCyte (MXCT) position with 6.53M shares
River Global Investors LLP has disclosed a 6.1% stake in MaxCyte, Inc. (MXCT), equating to 6,529,027 equity shares. The firm holds sole voting and dispositive power over these shares, which were acquired using investment capital through ordinary open-market transactions, including recent purchases on May 13, 2026. This indicates River Global's role as a financial investor rather than a strategic partner in MaxCyte.
River Global Investors Discloses Investment in MaxCyte with 6.1% Stake
River Global Investors LLP has disclosed a 6.095% stake in MAXCYTE, INC. after purchasing shares on the open market, crossing the 5% reporting threshold. The London-based firm acquired 650,000 shares at approximately $1.11 each on May 13, 2026, for funds it manages. No plans for board seats or significant changes at MaxCyte were indicated.
Stock Market Today: Dow Jones Futures Fall, S&P 500 Gains As Trump Takes Big Tech Leaders To China—Nvidia, Nextpower, Red Cat In Focus
U.S. stock futures showed mixed performance, with Dow Jones futures falling while S&P 500 and Nasdaq 100 rose, following President Donald Trump's visit to China with tech leaders like Nvidia CEO Jensen Huang. Several companies, including Nextpower, MaxCyte, and Taiwan Semiconductor Manufacturing, saw significant stock movement based on earnings and strategic announcements, while Red Cat Holdings plunged after a public offering. Professor Jeremy Siegel offered an optimistic market outlook, citing resilient labor data and the AI boom as key drivers, despite elevated S&P 500 valuations.
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue dips as expenses fall
MaxCyte (NASDAQ: MXCT) reported its Q1 2026 financial results, showing a decrease in revenue to $9.7 million from $10.4 million in the prior year, though the net loss narrowed significantly to $4.8 million from $10.3 million due to reduced operating expenses. The decline in revenue was attributed to weaker core product and license sales, partially offset by an increase in Strategic Platform License milestones and royalties. The company maintained a high gross margin of 84% and expects its existing cash and investments to fund operations for at least the next 12 months.
MaxCyte (MXCT) Earnings Call: Cash-Rich, Growth Delayed
MaxCyte's Q1 2026 earnings call revealed a company with strong cash reserves and reduced operating expenses, despite a sharp decline in core revenue. Management anticipates a recovery in the latter half of the year, driven by new product adoption and expanding strategic platform license (SPL) partnerships, as the company navigates a transitional period with external headwinds affecting immediate growth.
MaxCyte Q1 Earnings Call Highlights
MaxCyte reported a 7% decrease in Q1 2026 revenue to $9.7 million, with core revenue down 25% due to discontinued SPL programs and customer inventory management. Despite the decline, the company reiterated its full-year 2026 revenue guidance of $30 million to $32 million, anticipating a stronger second half driven by its ExPERT DTx product and easier comparisons. MaxCyte also highlighted progress in its SPL portfolio, CASGEVY royalties, SeQure business, and announced a $10 million share buyback, ending the quarter with $147.7 million in cash and no debt.
Press Release: MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MaxCyte has reported its first-quarter 2026 financial results, which include revenue figures for its Core Business and SPL Program. The company has also reaffirmed its financial guidance for the full year 2026, indicating confidence in its projected performance.
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue
MaxCyte (MXCT) exceeded first-quarter 2026 forecasts, reporting an EPS of -$0.04 against an expected -$0.08, and revenue of $9.7 million, significantly higher than the $7.3 million forecast. The company's stock rose 2.2% in aftermarket trading, driven by strong SPL program-related revenue growth despite an overall 7% decrease in total revenue year-over-year. MaxCyte reiterated its full-year 2026 guidance, expecting total revenue between $30 million and $32 million, and announced a $10 million share repurchase program, underscoring confidence in its long-term value and strategic investments.
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2026 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT) reported Q1 2026 earnings, discussing total revenue of $9.7 million, including $6.2 million from core activities and $3.4 million from milestone and royalty revenues. The company reiterated its full-year 2026 revenue guidance and announced a $10 million share repurchase program, reflecting confidence in its long-term value and strengthened financial position. Discussions also covered the progress of their ExPERT DTX product, SeQure assays, and the evolving landscape of cell and gene therapy, with a focus on later-stage clinical programs.
MaxCyte Q1 Earnings Call Highlights
MaxCyte reported a 7% decrease in Q1 2026 revenue to $9.7 million, with core revenue down 25% due to discontinued SPL programs and customer inventory management. Despite the decline, the company expects core revenue growth in the second half of 2026, driven by its new ExPERT DTx product and easier year-over-year comparisons, reiterating its full-year revenue guidance of $30 million to $32 million. MaxCyte also highlighted its SPL portfolio, progress with CASGEVY royalties, growth in its SeQure business, and cost reductions leading to a board-authorized share repurchase program.
Earnings Call Summary | MaxCyte(MXCT.US) Q1 2026 Earnings Conference
This document is an earnings call summary for MaxCyte (MXCT.US) for its Q1 2026 earnings conference. It provides details regarding the company's financial performance and operational highlights for the quarter.
MaxCyte Q1 Earnings Call Highlights
MaxCyte reported a 7% decrease in Q1 2026 total revenue to $9.7 million, with core revenue down 25% due to discontinued SPL programs and customer inventory management. Despite the decline, the company reiterated its full-year guidance, expecting second-half core revenue growth fueled by its ExPERT DTx product and easier year-over-year comparisons. MaxCyte highlighted its SPL portfolio, progress with CASGEVY royalties, growth in its SeQure business, and cost-cutting measures, alongside a new $10 million share repurchase authorization.
